Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Dec 15;102(12):2126–2135. doi: 10.1172/JCI4992

Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Y G Yang 1, B R Dey 1, J J Sergio 1, D A Pearson 1, M Sykes 1
PMCID: PMC509167  PMID: 9854048

Abstract

We have demonstrated that a single injection of interleukin (IL)-12 on the day of bone marrow transplantation (BMT) inhibits acute graft-versus-host disease (GVHD) in mice. This effect of IL-12 can be diminished by anti-interferon (IFN)-gamma mAb. To determine the mechanism by which IFN-gamma affects IL-12-mediated GVHD protection, we have compared the effect of IL-12 on GVHD in C57BL/6 wild-type (WT) or IFN-gamma gene knockout (GKO) recipients of fully major histocompatibility complex plus minor antigen-mismatched allogeneic BMT from WT or GKO BALB/c mice. Lethal acute GVHD was readily induced in the absence of IFN-gamma. IL-12 inhibited GVHD mortality to a similar extent in WT and GKO recipients of WT allogeneic BMT. However, neither WT nor GKO recipients were protected by IL-12 from GVHD induced by GKO allogeneic BMT. Moreover, the effective inhibition of host-reactive donor T cell activation and expansion that is associated with IL-12-mediated GVHD protection was dependent on the ability of BALB/c donors to produce IFN-gamma. These results demonstrate that (a) acute GVHD can be induced in the absence of IFN-gamma, (b) host IFN-gamma does not play a critical role in IL-12-induced GVHD protection, and (c) the protective effect of IL-12 against GVHD is dependent on the ability of the donor to produce IFN-gamma.

Full Text

The Full Text of this article is available as a PDF (207.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbas A. K., Murphy K. M., Sher A. Functional diversity of helper T lymphocytes. Nature. 1996 Oct 31;383(6603):787–793. doi: 10.1038/383787a0. [DOI] [PubMed] [Google Scholar]
  2. Allen R. D., Staley T. A., Sidman C. L. Differential cytokine expression in acute and chronic murine graft-versus-host-disease. Eur J Immunol. 1993 Feb;23(2):333–337. doi: 10.1002/eji.1830230205. [DOI] [PubMed] [Google Scholar]
  3. Antin J. H., Ferrara J. L. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992 Dec 15;80(12):2964–2968. [PubMed] [Google Scholar]
  4. Bradley L. M., Dalton D. K., Croft M. A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol. 1996 Aug 15;157(4):1350–1358. [PubMed] [Google Scholar]
  5. Brok H. P., Heidt P. J., van der Meide P. H., Zurcher C., Vossen J. M. Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol. 1993 Dec 1;151(11):6451–6459. [PubMed] [Google Scholar]
  6. Brok H. P., Vossen J. M., Heidt P. J. Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice. Bone Marrow Transplant. 1997 Mar;19(6):601–606. doi: 10.1038/sj.bmt.1700707. [DOI] [PubMed] [Google Scholar]
  7. Brunda M. J., Luistro L., Hendrzak J. A., Fountoulakis M., Garotta G., Gately M. K. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol. 1995 Feb;17(2):71–77. doi: 10.1097/00002371-199502000-00001. [DOI] [PubMed] [Google Scholar]
  8. Brunda M. J., Luistro L., Warrier R. R., Wright R. B., Hubbard B. R., Murphy M., Wolf S. F., Gately M. K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993 Oct 1;178(4):1223–1230. doi: 10.1084/jem.178.4.1223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brunda M. J., Sulich V., Bellantoni D. The anti-tumor effect of recombinant interferon alpha or gamma is influenced by tumor location. Int J Cancer. 1987 Dec 15;40(6):807–810. doi: 10.1002/ijc.2910400617. [DOI] [PubMed] [Google Scholar]
  10. Butturini A., Gale R. P. T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant. 1988 May;3(3):185–192. [PubMed] [Google Scholar]
  11. Böhm W., Thoma S., Leithäuser F., Möller P., Schirmbeck R., Reimann J. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol. 1998 Jul 15;161(2):897–908. [PubMed] [Google Scholar]
  12. Dalton D. K., Pitts-Meek S., Keshav S., Figari I. S., Bradley A., Stewart T. A. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993 Mar 19;259(5102):1739–1742. doi: 10.1126/science.8456300. [DOI] [PubMed] [Google Scholar]
  13. Dey B. R., Yang Y. G., Szot G. L., Pearson D. A., Sykes M. Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion. Blood. 1998 May 1;91(9):3315–3322. [PubMed] [Google Scholar]
  14. Ellison C. A., Fischer J. M., HayGlass K. T., Gartner J. G. Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors. J Immunol. 1998 Jul 15;161(2):631–640. [PubMed] [Google Scholar]
  15. Fowler D. H., Kurasawa K., Husebekk A., Cohen P. A., Gress R. E. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol. 1994 Feb 1;152(3):1004–1013. [PubMed] [Google Scholar]
  16. Garvy B. A., Gigliotti F., Harmsen A. G. Neutralization of interferon-gamma exacerbates pneumocystis-driven interstitial pneumonitis after bone marrow transplantation in mice. J Clin Invest. 1997 Apr 1;99(7):1637–1644. doi: 10.1172/JCI119326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Guy-Grand D., Vassalli P. Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms. J Clin Invest. 1986 May;77(5):1584–1595. doi: 10.1172/JCI112474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Holda J. H., Maier T., Claman H. N. Evidence that IFN-gamma is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation. 1988 Apr;45(4):772–777. doi: 10.1097/00007890-198804000-00021. [DOI] [PubMed] [Google Scholar]
  19. Klimpel G. R., Annable C. R., Cleveland M. G., Jerrells T. R., Patterson J. C. Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN-gamma production. J Immunol. 1990 Jan 1;144(1):84–93. [PubMed] [Google Scholar]
  20. Konieczny B. T., Dai Z., Elwood E. T., Saleem S., Linsley P. S., Baddoura F. K., Larsen C. P., Pearson T. C., Lakkis F. G. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol. 1998 Mar 1;160(5):2059–2064. [PubMed] [Google Scholar]
  21. Krenger W., Falzarano G., Delmonte J., Jr, Snyder K. M., Byon J. C., Ferrara J. L. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood. 1996 Aug 1;88(3):1113–1121. [PubMed] [Google Scholar]
  22. Krenger W., Snyder K. M., Byon J. C., Falzarano G., Ferrara J. L. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995 Jul 15;155(2):585–593. [PubMed] [Google Scholar]
  23. Krenger W., Snyder K., Smith S., Ferrara J. L. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation. 1994 Dec 15;58(11):1251–1257. [PubMed] [Google Scholar]
  24. Liu Y., Janeway C. A., Jr Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med. 1990 Dec 1;172(6):1735–1739. doi: 10.1084/jem.172.6.1735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Magram J., Connaughton S. E., Warrier R. R., Carvajal D. M., Wu C. Y., Ferrante J., Stewart C., Sarmiento U., Faherty D. A., Gately M. K. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity. 1996 May;4(5):471–481. doi: 10.1016/s1074-7613(00)80413-6. [DOI] [PubMed] [Google Scholar]
  26. Manetti R., Parronchi P., Giudizi M. G., Piccinni M. P., Maggi E., Trinchieri G., Romagnani S. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993 Apr 1;177(4):1199–1204. doi: 10.1084/jem.177.4.1199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Martin P. J., Hansen J. A., Torok-Storb B., Durnam D., Przepiorka D., O'Quigley J., Sanders J., Sullivan K. M., Witherspoon R. P., Deeg H. J. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 1988 Sep;3(5):445–456. [PubMed] [Google Scholar]
  28. Mowat A. M. Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology. 1989 Sep;68(1):18–23. [PMC free article] [PubMed] [Google Scholar]
  29. Nastala C. L., Edington H. D., McKinney T. G., Tahara H., Nalesnik M. A., Brunda M. J., Gately M. K., Wolf S. F., Schreiber R. D., Storkus W. J. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994 Aug 15;153(4):1697–1706. [PubMed] [Google Scholar]
  30. Niederwieser D., Herold M., Woloszczuk W., Aulitzky W., Meister B., Tilg H., Gastl G., Bowden R., Huber C. Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation. 1990 Oct;50(4):620–625. doi: 10.1097/00007890-199010000-00019. [DOI] [PubMed] [Google Scholar]
  31. Noguchi Y., Jungbluth A., Richards E. C., Old L. J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11798–11801. doi: 10.1073/pnas.93.21.11798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Novelli F., Bernabei P., Ozmen L., Rigamonti L., Allione A., Pestka S., Garotta G., Forni G. Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. J Immunol. 1996 Sep 1;157(5):1935–1943. [PubMed] [Google Scholar]
  33. Novelli F., D'Elios M. M., Bernabei P., Ozmen L., Rigamonti L., Almerigogna F., Forni G., Del Prete G. Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. J Immunol. 1997 Jul 1;159(1):206–213. [PubMed] [Google Scholar]
  34. Novelli F., Di Pierro F., Francia di Celle P., Bertini S., Affaticati P., Garotta G., Forni G. Environmental signals influencing expression of the IFN-gamma receptor on human T cells control whether IFN-gamma promotes proliferation or apoptosis. J Immunol. 1994 Jan 15;152(2):496–504. [PubMed] [Google Scholar]
  35. Poynton C. H. T cell depletion in bone marrow transplantation. Bone Marrow Transplant. 1988 Jul;3(4):265–279. [PubMed] [Google Scholar]
  36. Rossi A. R., Pericle F., Rashleigh S., Janiec J., Djeu J. Y. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood. 1994 Mar 1;83(5):1323–1328. [PubMed] [Google Scholar]
  37. Schijns V. E., Haagmans B. L., Horzinek M. C. IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice. J Immunol. 1995 Sep 1;155(5):2525–2532. [PubMed] [Google Scholar]
  38. Seder R. A., Gazzinelli R., Sher A., Paul W. E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10188–10192. doi: 10.1073/pnas.90.21.10188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Soiffer R. J., Robertson M. J., Murray C., Cochran K., Ritz J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood. 1993 Nov 1;82(9):2790–2796. [PubMed] [Google Scholar]
  40. Swihart K., Fruth U., Messmer N., Hug K., Behin R., Huang S., Del Giudice G., Aguet M., Louis J. A. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med. 1995 Mar 1;181(3):961–971. doi: 10.1084/jem.181.3.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Sykes M., Abraham V. S., Harty M. W., Pearson D. A. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol. 1993 Jan 1;150(1):197–205. [PubMed] [Google Scholar]
  42. Sykes M., Romick M. L., Hoyles K. A., Sachs D. H. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med. 1990 Mar 1;171(3):645–658. doi: 10.1084/jem.171.3.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sykes M., Szot G. L., Nguyen P. L., Pearson D. A. Interleukin-12 inhibits murine graft-versus-host disease. Blood. 1995 Sep 15;86(6):2429–2438. [PubMed] [Google Scholar]
  44. Szebeni J., Wang M. G., Pearson D. A., Szot G. L., Sykes M. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease. Transplantation. 1994 Dec 27;58(12):1385–1393. [PubMed] [Google Scholar]
  45. Tannenbaum C. S., Wicker N., Armstrong D., Tubbs R., Finke J., Bukowski R. M., Hamilton T. A. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol. 1996 Jan 15;156(2):693–699. [PubMed] [Google Scholar]
  46. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol. 1981 Apr;126(4):1614–1619. [PubMed] [Google Scholar]
  47. Tsutsui T., Mu J., Ogawa M., Yu W. G., Suda T., Nagaga S., Saji F., Murata Y., Fujiwara H., Hamaoka T. Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells. J Immunol. 1997 Sep 15;159(6):2599–2605. [PubMed] [Google Scholar]
  48. Unkeless J. C. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med. 1979 Sep 19;150(3):580–596. doi: 10.1084/jem.150.3.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Verdonck L. F., van Blokland W. T., Bosboom-Kalsbeek E. K., van Heugten H. G., Tilanus M. G., de Weger R. A. Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T cells. Bone Marrow Transplant. 1996 Aug;18(2):389–395. [PubMed] [Google Scholar]
  50. Via C. S., Rus V., Gately M. K., Finkelman F. D. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol. 1994 Nov 1;153(9):4040–4047. [PubMed] [Google Scholar]
  51. Wall D. A., Hamberg S. D., Reynolds D. S., Burakoff S. J., Abbas A. K., Ferrara J. L. Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression. J Immunol. 1988 May 1;140(9):2970–2976. [PubMed] [Google Scholar]
  52. Wall D. A., Sheehan K. C. The role of tumor necrosis factor and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation. 1994 Jan;57(2):273–279. doi: 10.1097/00007890-199401001-00021. [DOI] [PubMed] [Google Scholar]
  53. Wang Z. E., Zheng S., Corry D. B., Dalton D. K., Seder R. A., Reiner S. L., Locksley R. M. Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12932–12936. doi: 10.1073/pnas.91.26.12932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Wenner C. A., Güler M. L., Macatonia S. E., O'Garra A., Murphy K. M. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol. 1996 Feb 15;156(4):1442–1447. [PubMed] [Google Scholar]
  55. Williamson E., Garside P., Bradley J. A., More I. A., Mowat A. M. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J Immunol. 1997 Aug 1;159(3):1208–1215. [PubMed] [Google Scholar]
  56. Williamson E., Garside P., Bradley J. A., Mowat A. M. IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol. 1996 Jul 15;157(2):689–699. [PubMed] [Google Scholar]
  57. Yang Y. G., Dey B., Sergio J. J., Sykes M. Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model. Transplantation. 1997 Nov 15;64(9):1343–1352. doi: 10.1097/00007890-199711150-00018. [DOI] [PubMed] [Google Scholar]
  58. Yang Y. G., Sergio J. J., Pearson D. A., Szot G. L., Shimizu A., Sykes M. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood. 1997 Dec 1;90(11):4651–4660. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES